Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries is currently trading at Rs. 751.70, up by 11.80 points or 1.59% from its previous closing of Rs. 739.90 on the BSE.

The scrip opened at Rs. 743.00 and has touched a high and low of Rs. 757.40 and Rs. 742.35 respectively. So far 380412 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 965.15 on 20-Aug-2015 and a 52 week low of Rs. 706.40 on 24-Nov-2015.

Last one week high and low of the scrip stood at Rs. 758.00 and Rs. 732.00 respectively. The current market cap of the company is Rs. 181192.47 crore.

The promoters holding in the company stood at 54.97%, while Institutions and Non-Institutions held 35.37% and 9.66% respectively.

Sun Pharmaceutical Industries has recalled around 2,839 bottles of anti-bacterial medicine Nitrofurantoin Oral Suspension in the US market on account of failed dissolution specifications. The ongoing voluntary recall by Nostrum Laboratories for Nitrofurantoin Oral Suspension, USP, 25 mg/5 mL is a class II recall. The 2,839 bottles were manufactured and distributed by Sun Pharmaceutical Industries.

According to USFDA, a class II recall is initiated in a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote. Nitrofurantoin oral suspension, USP is specifically indicated for the treatment of urinary tract infections.

Sun Pharma is the world's fifth largest specialty generic pharmaceutical company and India's top pharmaceutical company. A vertically integrated business, economies of scale and an extremely skilled team enable us to deliver quality products in a timely manner at affordable prices. It provides high-quality, affordable medicines trusted by customers and patients in over 150 countries across the world.